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Abstract
While the induction of broadly neutralizing antibodies (bNAbs) is a major goal of HIV vaccina-
tion strategies, there is mounting evidence to suggest that antibodies with Fc effector function
also contribute to protection against HIV infection. Here we investigated Fc effector function-
ality of HIV-specific IgG plasma antibodies over 3 years of infection in 23 individuals, 13 of
whom developed bNAbs. Antibody-dependent cellular phagocytosis (ADCP), complement
deposition (ADCD), cellular cytotoxicity (ADCC) and cellular trogocytosis (ADCT) were
detected in almost all individuals with levels of activity increasing over time. At 6 months post-
infection, individuals with bNAbs had significantly higher levels of ADCD and ADCT that cor-
related with antibody binding to C1q and FcγRIIa respectively. In addition, antibodies from
individuals with bNAbs showed more IgG subclass diversity to multiple HIV antigens which
also correlated with Fc polyfunctionality. Germinal center activity represented by CXCL13
levels and expression of activation-induced cytidine deaminase (AID) was found to be associ-
ated with neutralization breadth, Fc polyfunctionality and IgG subclass diversity. Overall, mul-
tivariate analysis by random forest classification was able to group bNAb individuals with
85% sensitivity and 80% specificity based on the properties of their antibody Fc early in HIV
infection. Thus, the Fc effector function profile predicted the development of neutralization
breadth in this cohort, suggesting that intrinsic immune factors within the germinal center pro-
vide a mechanistic link between the Fc and Fab of HIV-specific antibodies.
Author summary
Some HIV-infected individuals develop antibodies that are capable of neutralizing the
majority of HIV strains, a highly desirable function mediated by the antibody Fab portion.
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While antibodies elicited by current vaccines have failed to recreate this activity, the par-
tial protection seen in the RV144 vaccine trial has been attributed to antibody Fc-medi-
ated effector functions such as cell killing. In this study, we found that HIV-infected
individuals who show a diversified and potent Fc response early in infection were more
likely to develop broadly neutralizing antibodies later on. Examination of B cell functions
associated with good germinal center activity, provided evidence for a common mechanis-
tic link between the regulation of the Fc and Fab mediated activities in these individuals.
Our finding of an Fc effector function profile that arises early and predicts neutralization
breadth could be used in the evaluation of vaccine candidates designed to generate neu-
tralizing antibodies. Common immune determinants associated with both Fab and Fc
function could furthermore be exploited for vaccine design to harness the full potential of
HIV-specific antibodies.
Introduction
Antibodies form a link between the adaptive and innate immune systems and serve as a corre-
late of protection for many viral vaccines. They mediate diverse functions through the use of
the Fab portion to bind specific antigens and the Fc portion that interacts with cellular recep-
tors to effect a variety of additional non-neutralizing activities [1]. As yet, no HIV vaccine has
been able to elicit broadly neutralizing antibodies (bNAbs), however moderate efficacy in the
RV144 vaccine trial correlated with Fc-mediated antibody-dependent cellular cytotoxicity
(ADCC) in the absence of IgA response generating intense interest in understanding how
these responses evolve [2–8]. Maturation of antibodies occurs in the germinal center where
they undergo somatic hypermutation to generate high affinity neutralizing antibodies, as well
as class-switch recombination to select constant regions that determine the scope of Fc effector
functions. Both processes are dependent on the enzyme activation-induced cytidine deaminase
(AID) as well as the cytokine milieu within the germinal center, suggesting that the Fab and Fc
maturation processes of antigen-specific antibodies may be jointly regulated [9–11].
Although current vaccination strategies are unable to induce bNAbs, approximately 10–30%
of individuals produce bNAbs during the course of HIV infection, with only 1–2% classified as
elite neutralizers [12–16]. Several factors have been associated with the development of neutrali-
zation breadth, including duration of infection, high viral load, low CD4 count, genetic subtype
and viral diversity [12, 13, 16–18]. The role of host immunological factors is less clear but in-
cludes the maintenance of a high level of T follicular helper cells, increased levels of CXCL13
early in infection, autoimmunity and ethnicity [16, 19–22]. Isolation of bNAbs has revealed that
they have unusual features, most notably a high level of somatic hypermutation, which is essen-
tial for mediating neutralizing activity [23, 24]. Given the importance of bNAbs for HIV vaccine
design, considerable effort has been invested in understanding how these antibodies evolve
[25]. However, far less is known about the corresponding Fc effector response and IgG subclass
usage in individuals who develop neutralization breadth.
The antibody Fc portion mediates a wide range of functions that are dependent on their
affinity for activating and inhibiting Fc receptors, lectins and complement proteins [26]. These
functions include phagocytosis of pathogens by macrophages and monocytes, ADCC or direct
lysis by natural killer cells, complement deposition and trogocytosis, an Fc dependent exchange
of membrane proteins on the surface of an infected to an uninfected cell which may result in
cell death [27, 28] (Richardson, et al., submitted). Fc effector functions are modulated at the B
cell level by biochemical properties such as glycosylation at a conserved site in the CH2 region
Fc effector function and HIV neutralization breadth
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and isotype or subclass selection determined by the cytokine milieu in the germinal centers
[29–32]. Affinity and specificity for the antigen as determined by the Fab portion has also been
shown to impact Fc effector functions [33–35].
Several studies have shown that Fc effector function may influence HIV disease progres-
sion, viral control and infant mortality [36–43]. Co-ordination between Fc effector functions
has also been associated with HIV control [43, 44], which was also observed in the responses
to the partially protective RV144 vaccine [3, 5]. Furthermore, protective immunity in an ade-
novirus-26 based vaccine in primates was linked to Fc polyfunctionality [45]. However, direct
evidence that non-neutralizing antibodies can protect via Fc-mediated functions is limited
[46–48] although one study showed a reduced number of transmitted/founder viruses as a
result of Fc activity [49]. More recently, non-neutralizing mAbs have been shown to clear
HIV-infected cells and protect against infection in humanized mice, despite being less effective
than bNAbs [50]. Perhaps more convincing is the accumulating evidence that Fc binding is
required for bNAbs to optimally protect from infection, supress viral load or clear infected
cells [51–55].
This study aimed to investigate Fc effector functions and kinetics in the context of a broad
neutralizing response. Furthermore, we examine potential modulators of this response includ-
ing binding to Fc receptors, IgG subclass diversity and the interplay between germinal center
activity, Fc polyfunctionality and neutralization breadth. Our data show that individuals with
bNAbs also have higher Fc polyfunctionality and increased subclass diversity, which was asso-
ciated with greater AID expression in B cells. This study suggests that the Fc and Fab portions
of HIV-specific antibodies are co-ordinately regulated and identifies an Fc effector profile that
is associated with the development of bNAbs.
Results
HIV-specific Fc effector functions in individuals with and without bNAbs
We aimed to determine whether individuals with HIV-1 specific bNAbs showed differences in
Fc effector functions and what the kinetics of these responses were relative to the development
of neutralization breadth. Plasma IgG was isolated from 13 bNAb and 10 no-bNAb individuals
at 6, 12 and 36 months post-infection matched for viral load (S1 Table and S1A Fig), a major
driver of immune activation and neutralization breadth [12, 56]. These were tested in 4 differ-
ent Fc effector assays measuring ADCC (% granzyme B release), ADCP (% fluorescent bead
phagocytosed x MFI of phagocytosed beads), ADCD (% C3b deposition x MFI of deposited
C3b) and ADCT (% PKH-26 stained membrane transferred to CFSE+ macrophages). Three
different HIV envelope glycoproteins were used to detect HIV-specific Fc responses including
gp120 ConC, gp140 C.ZA.1197MB and gp120 CAP45. Transmitted/founder or acute viruses
from 10 bNAb and 7 no-bNAb individuals for which sequences were available were used to
calculate divergence from the sequence of the three antigens. We found that both groups
showed equivalent levels of sequence divergence from each antigen, indicating no bias in
terms of antigen binding based on autologous virus sequence (S1B Fig). Furthermore, analysis
of longitudinal gp160 sequences in 8 bNAb and 5 no-bNAb individuals with available data
showed that viral diversity did not differ between the 2 groups, perhaps not unexpected given
they were matched for viral load (S1C Fig).
IgG from almost all individuals, irrespective of the presence of bNAbs, had Fc effector func-
tion activity with ADCP and ADCD being the most readily detectable, particularly in response
to gp120 ConC (Fig 1A). At 6 months of infection, IgG from bNAb individuals showed signifi-
cantly higher ADCD against gp120 ConC (p = 0.030), gp140 (p = 0.042) and gp120 CAP45
(p = 0.047) compared to no-bNAb individuals. This was also noted at 12 months for gp140
Fc effector function and HIV neutralization breadth
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(p = 0.030) (S2 Fig). ADCT was higher in bNAb individuals at both 6 and 12 months post-
infection against gp120 ConC (p = 0.002; p = 0.030) and gp140 (p = 0.004; p = 0.014). There
was no difference observed between the 2 groups for ADCC and ADCP against any of the anti-
gens tested but all were significantly higher than the HIV-negative IgG control.
A comparison of the cumulative activity of all 4 Fc effector functions against all 3 antigens
over 36 months of infection between the two groups highlighted the differences seen at 6
months (Figs 1B and S2). Significant increases over time were noted primarily in the no-bNAb
group for ADCD and ADCC and in the bNAb group for ADCT while high levels of ADCP
were maintained in both groups (S2 Fig). No-bNAb individuals had a steeper increase in
Fig 1. Fc effector function early in HIV infection is higher in individuals that develop bNAbs. (A) Purified IgG from 13 bNAb, 10 no-bNAb and 5 HIV-
negative individuals (in red, blue and grey respectively) at 6 months post-infection was tested for antibody dependent cellular phagocytosis (ADCP), complement
deposition (ADCD), cellular trogocytosis (ADCT) and cellular cytoxicity (ADCC) using three HIV-specific antigens gp120 ConC, gp140 C.ZA.1197MB and gp120
CAP45.G3. Significant differences between groups determined by the Mann-Whitney U test are indicated by p<0.05; p<0.001. (B) Medians and IQR of
different Fc effector functions for bNAb and no-bNAb individuals against all tested antigens over 36 months of infection are indicated as cumulative Fc effector
function. Data are representative of 3 independent experiments. (C) Each Fc function was standardized by calculating a Z-score and polyfunctionality determined
by addition of the Z-scores for all functions for each individual. Bars above the x-axis indicate Fc polyfunctional individuals, while those below indicate poor Fc
polyfunctionality. bNAb and no-bNAb individuals are indicated in red and blue respectively. (D) Spearman´s correlation coefficient for the relationship between
the Fc polyfunctionality Z-score and % neutralization breadth calculated by a 44 multi-clade virus panel is shown. The dashed diagonal line indicates the trend of
the relationship.
https://doi.org/10.1371/journal.ppat.1006987.g001
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function over time, as a result of a lower initial Fc effector response. Regardless of neutraliza-
tion breadth, Fc effector function in both groups was comparable by 36 months. Adsorption of
broad neutralizing activity from an individual with bNAbs (CAP255) revealed a significant
3-fold reduction in ADCC, ADCP and 2-fold reduction in ADCD against gp120 ConC com-
pared to the unadsorbed IgG (S3 Fig). This suggests that the N332-specific antibodies that
mediate broad neutralizing activity in CAP255 [12], were also responsible for a significant pro-
portion of Fc effector functionality.
Individuals with bNAbs show a distinct Fc effector polyfunction profile
In order to account for the contributions of all four effector functions equitably, we calculated
an Fc polyfunctionality Z-score using the gp120 ConC data from 6 months post-infection.
Z-scores with values greater than zero indicated samples with good Fc polyfunctional activity.
Of the 13 bNAb individuals, 8 showed positive Z-scores compared to only 1 of the no-bNAb
individuals who had a weakly positive Z-score (Fig 1C). The remaining 9 no-bNAb samples
had negative Z-scores compared to 5 in the bNAb group. Thus IgG samples from individuals
who later went on to develop bNAbs could be distinguished from no-bNAb individuals on the
basis of their higher overall polyfunctional polyclonal response against gp120 ConC early in
infection. Furthermore, neutralization breadth measured at 3 years post-infection correlated
significantly with the Fc polyfunctionality Z-score calculated using data from 6 months of
infection (r = 0.45, p = 0.030, Fig 1D). There was also a correlation between these gp120 ConC
Z-scores and those calculated using gp140 (r = 0.69, p<0.001, S4A Fig), an antigen that also
showed a significant correlation with neutralization breadth (S4B Fig). Fc polyfunctionality
Z-scores calculated using CAP45.G3 gp120 did not distinguish bNAb individuals unlike the
other 2 antigens (Figs 1C and S4). This is likely to be as a result of CAP45.G3 gp120 having sig-
nificantly lower titers of binding IgG antibodies than both ConC gp120 and C.ZA1197MB
gp140 (S5A Fig). In order to assess collaboration between different Fc effector functions, corre-
lation coefficients between the functions were calculated. There was significant discordance in
the no-bNAb group with negative correlations noted between ADCP and all other functions
and concordance between ADCT and ADCD (S4C Fig). In contrast, the bNAb group showed
no significant discordance or concordance between Fc effector functions, further highlighting
that individuals with and without bNAbs have distinct Fc effector function profiles early in
HIV infection.
Antibody binding to Fc receptors and complement is significantly higher in
individuals with bNAbs
Since antibody function is modulated by binding to different Fc receptors and complement
proteins, we assessed the binding of gp120 ConC-specific IgG to 6 different Fc receptors and
C1q (the first subcomponent of the C1 complex of the classical pathway of complement activa-
tion) using a multiplex-based assay (as described in [57]). Polymorphisms of the FcγRIIa (both
R131 and H131) and FcγRIIIa (both F158 and V158) receptors that affect IgG binding and
impact HIV disease progression (reviewed in [58]) were also tested. Individuals with bNAbs
had significantly higher levels of binding to all receptors except FcγRIIa-R131 where only a
trend was evident (Fig 2A). Since FcγRIIa is the primary receptor that mediates phagocytosis
and this process is negatively regulated by FcγRIIb [59], an increase in binding to both activat-
ing and inhibitory receptors among bNAb individuals was somewhat unexpected given that
we observed no differences in phagocytosis between the two groups (Fig 1A). We therefore
determined the ratio of antibody binding to these 2 receptors which has previously been
shown to correlate with phagocytic function [59, 60]. Here we found no differences between
Fc effector function and HIV neutralization breadth
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the bNAb and no-bNAb groups irrespective of the FcγRIIa-H131/R131 genotype which was
more consistent with the finding of similar ADCP levels in the two groups (Fig 2B). ADCT
correlated with binding to FcγRIIa and FcγRIIIa (Fig 2C), two receptors that have been impli-
cated in mediating this function [61, 62] (Richardson, et al., submitted). In addition, we found
several correlations for ADCD including FcγRIIa-R131, FcγRIIb and FcγRIIIb, however C1q
Fig 2. IgG isolated from individuals that develop bNAbs shows increased gp120-specific binding to Fc receptors and complement proteins. (A) Binding
gp120 ConC-specific IgG isolated from bNAb (red) and no-bNAb (blue) individuals to Fc receptors and C1q measured by an antigen-specific Fc receptor
multiplex array. Significant differences (calculated by Mann-Whitney U test) in binding are shown as p<0.05; p<0.001; p<0.0001. Data are
representative of 2 independent experiments. (B) The ratio of activating FcγRIIa (either H131 or R131) to inhibitory FcγRIIb receptor binding at 6 months post
infection for bNAb and no-bNAb individuals. Medians are shown and significance was calculated by the Mann-Whitney U test. (C) Correlations between
ADCT or ADCD and binding to Fc receptors and C1q shown as MFI. Significant Spearman´s correlation coefficients are indicated. Lines indicate the trend of
the correlations.
https://doi.org/10.1371/journal.ppat.1006987.g002
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showed the strongest correlation consistent with this being the primary binding protein for
complement deposition (r = 0.65; p<0.001).
Individuals who develop bNAbs have a greater IgG subclass diversity
IgG comprises 4 subclasses each with distinct Fc regions that bind differentially to cellular Fc
receptors and complement proteins. Using an antigen-specific IgG subclass multiplex assay,
we measured the levels of IgG1-4 and total IgG against 12 HIV antigens including trimeric
envelope, gp140, monomeric gp120, V2, V3, gp41, membrane proximal external region
(MPER) and p24. First, to determine if there was any IgG subclass bias of antibodies able to
mediate Fc effector functions, we analysed 6-month data with gp120 ConC as this antigen was
used in all assays. Other than gp120-specific total IgG that was significantly associated with
ADCD (r = 0.74; p<0.001) and ADCC (r = 0.46, p = 0.010), only ADCT was shown to corre-
late with HIV-specific IgG3 (r = 0.48; p = 0.02) suggesting that multiple rather than single sub-
classes mediate Fc effector functions (S5B Fig). Our earlier finding that bNAb individuals had
greater binding to FcγRIIa-H131 and FcγRIIIa-V158 (Fig 2A), receptors known to bind IgG2
and IgG4 [63] led us to explore whether individuals with bNAbs had a greater diversity of IgG
subclasses specific to HIV. While there were no significant differences in HIV-specific IgG1
and IgG3 levels (as a proportion of total antigen-specific IgG) individuals with bNAbs showed
significantly higher IgG2 and IgG4 binding to 7 of the 12 antigens tested, including BG505
SOSIP.664 gp140 trimeric protein (S6 Fig). This was also reflected when we represented the
less frequent subclasses (IgG2, IgG3 and IgG4) as a proportion of IgG1 (Fig 3A). Overall, we
noted that individuals who developed bNAbs showed a greater relative abundance of IgG2 and
IgG4 to IgG1. In particular, IgG2 binding to MPER and p24 antigens and IgG4 binding to the
A244 V2 antigen, gp120 ConC and gp41 were higher among bNAb individuals. Among the
no-bNAb samples, levels of IgG2 and IgG4 were considerably lower with only a V2 antigen
and p24 showing some reactivity. We calculated a subclass diversity score based on levels of
IgG2 plus IgG4 relative to IgG1 and found this to be correlated with neutralization breadth
(r = 0.40, p = 0.049, Fig 3B) and the Fc polyfunctionality Z-score (r = 0.43, p = 0.040, Fig 3C).
These data suggested that individuals who develop bNAbs in chronic infection undergo
increased IgG class switching within the first 6 months of infection.
Germinal center activity and AID expression is higher in individuals with
bNAbs and associated with Fc polyfunctionality and IgG subclass diversity
Both class switch recombination and somatic hypermutation take place in germinal centers
and are enabled by activation-induced cytidine deaminase (or AID) as well as interactions
between T helper follicular (Tfh) cells with B cells. The cytokine CXCL13, expressed by Tfh
cells [64, 65], has been shown to correlate with neutralization breadth early in HIV infection
and is defined as a marker of germinal center activity [19–21, 56, 66]. We measured CXCL13
levels in plasma by enzyme linked immunosorbent assay (ELISA) and found significantly
higher levels in individuals with bNAbs at 6 months post infection (p = 0.002) but not at later
time points (Fig 4A). HIV-negative samples were significantly lower than HIV-positive plasma
(p<0.001) similar to other studies showing that HIV infection is associated with increased
expression of this cytokine [21]. The levels of CXCL13 at 6 months were also correlated with
neutralization breadth (r = 0.52, p = 0.010, Fig 4B) and Fc polyfunction measured against
gp120 ConC (r = 0.60, p = 0.003, Fig 4C). CXCL13 was not correlated with IgG subclass diver-
sity or total IgG levels.
We next directly measured AID in B cells from 6 bNAb individuals and 6 no-bNAb individ-
uals from 6 months post infection, from whom PBMC were available. In order to detect AID
Fc effector function and HIV neutralization breadth
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006987 April 9, 2018 7 / 25
Fig 3. bNAb individuals have higher HIV-specific IgG subclass diversity. (A) A multiplex assay was used to measure levels of HIV-specific IgG subclasses
present in 6 month samples from bNAb and no-bNAb individuals to 12 different HIV antigens. Median abundance of antigen-specific IgG2, IgG3 and IgG4
(orange, yellow and purple respectively) are represented as a ratio to IgG1 calculated using median fluorescence intensities. Data are representative of 2
independent experiments. Spearman´s correlations between subclass diversity score and (B) neutralization breadth and (C) Fc polyfunctionality are shown. The
score was calculated as the ratio of gp120 ConC IgG2 and IgG4 relative to IgG1 levels. bNAb individuals are shown in red and no-bNAb in blue with dotted trend
lines.
https://doi.org/10.1371/journal.ppat.1006987.g003
Fc effector function and HIV neutralization breadth
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006987 April 9, 2018 8 / 25
at a reliable level we stimulated PBMCs for 3 days with TLR9 and confirmed stimulation by
the co-staining of live B cells (defined as CD3/CD16/CD14- CD19+ as in S7A Fig) with AID
and with Ki67 (a marker of proliferating cells). As expected, stimulation increased the percent-
age of B cells expressing AID but no significant difference was observed among the 2 groups
or HIV-negative individuals (S7B Fig). However, when AID expression was measured by the
mean fluorescence intensity (MFI) of AID, we noted significantly higher expression of AID in
stimulated B cells from individuals with bNAbs compared to no-bNAbs and HIV-negative
individuals (p = 0.010, Kruskal-Wallis test with Tukey correction for multiple comparisons,
Fig 4D). Even on unstimulated B cells, median AID expression levels tended to be higher in
bNAb individuals. Interestingly, both neutralization breadth (r = 0.58; p = 0.040, Fig 4E) and
IgG subclass diversity (r = 0.60, p = 0.040, Fig 4F) correlated with AID expression suggesting
germinal center activity not only plays a role in the development of bNAbs but is also an indi-
cator of enhanced Fc effector function.
Random forest classification defines bNAb individuals based on Fc effector
functions
In order to ascertain which of the 29 variables examined in this study were best able to separate
bNAb from no-bNAb individuals, we used Spearman’s correlations that were adjusted for
Fig 4. CXCL13 and AID correlate with neutralization breadth, subclass diversity and Fc polyfunctionality. (A) Germinal center activity as represented by
CXCL13 levels were measured by ELISA in plasma (pg/ml) at 6, 12 and 36 months post infection from 13 bNAb (red), 10 no-bNAb (blue) and 4 HIV-negative
individuals (grey). Significance was defined by the Kruskal-Wallis test with Tukey correction where p = 0.002 and p<0.0001. Median values are shown and
results are representative of 3 independent experiments. Significant Spearman´s correlations at 6 months post-infection between CXCL13 and (B) neutralization
breadth and (C) Fc polyfunctionality are shown. (D) AID was measured in B cells in peripheral blood from 6 bNAb (red), 6 no-bNAb (blue) and 4 HIV-negative
(grey) individuals by flow cytometry after stimulation and activation with TLR9 for 3 days. AID expression in live B cells is represented by AID MFI and
significance is indicated as p<0.05, Kruskal-Wallis test with Tukey correction in TLR9 stimulated B cells. (UN = unstimulated; TLR9 = TLR9 stimulated).
Significant Spearman´s correlations between AID expression and (E) neutralization breadth and (F) subclass diversity (calculated by gp120 ConC specific IgG2
+IgG4/IgG1) are shown. Dotted trend lines are indicated.
https://doi.org/10.1371/journal.ppat.1006987.g004
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multiple comparisons by the Benjamini–Hochberg method (S2 Table). Owing to the small
sample size of the individuals tested for AID, this variable was omitted. Subclass diversity, Fc
receptor and C1q binding antibodies targeting gp120 from both CAP45 and ConC, Fc poly-
functionality and CXCL13 were all significantly associated with the bNAb group. CD4 count
was significantly negatively associated with the bNAb group and, as expected, we saw no asso-
ciation with viral load due to matching of the two groups for this variable. The 17 variables
that showed significance, were used in further statistical analyses to refine groupings. When
subjected to a principal components analysis, the sum of the first 2 components were able to
explain 52.3% of the variability of the data set (Fig 5A). Furthermore, when random forest clas-
sification was used to define bNAb and no-bNAb groups, it did so with 85% sensitivity 80%
specificity, and 82.6% accuracy, only misidentifying 2 bNAb and 2 no-bNAb individuals
shown in the confusion matrix in Fig 5B. The features important for this classification are rep-
resented by the Gini importance weighting, and identified increased binding to gp120 ConC
FcγRIIIa-V158, low CD4 count, gp120 ConC-specific total IgG and Fc polyfunction for gp120
ConC and gp140 as being the best features to classify bNAb individuals (Fig 5C). We then
tested the strength of the model by permutation testing, allowing for 100,000 random data
shuffles, revealing that there was a 0.38% probability that the same model could be obtained at
random (Fig 5D). Collectively, these analyses indicate that Fc properties can be used to reliably
discriminate between individuals who develop bNAbs from those who do not.
Discussion
In this study, we found that HIV-infected individuals who develop bNAbs also have a distinct
Fc effector function profile and increased subclass diversity associated with markers of en-
hanced germinal center activity. Specifically, these individuals showed more potent trogocyto-
sis and complement deposition as well as IgG2 and IgG4 responses to multiple HIV antigens
early in infection compared to individuals who did not develop bNAbs. Interestingly, both
CXCL13 levels in plasma and AID expression levels in activated B cells correlated with neutral-
ization breadth and Fc polyfunctionality. Our data suggest that markers of germinal center
activity that link Fab and Fc could be exploited for vaccine design to harness the full potential
of HIV-specific antibodies.
To conduct this study we made use of longitudinal samples collected from HIV-1 infected
participants in the CAPRISA acute infection cohort in which the development of bNAbs has
been well described [12]. We selected all 13 participants who developed bNAbs by 3 years of
infection as well as 10 matched no-bNAb controls. Less than 20% of individuals in the CAPRISA
cohort developed bNAbs, similar to many other studies, and so we selected all 13 available
bNAb individuals and matched them to those with no-bNAbs that had similar viral levels. While
this is not representative of the general population, our aim was to compare those 2 distinct phe-
notypes in order to maximize our ability to detect differences associated with bNAb develop-
ment. We found that, unlike neutralization, Fc effector function was detected early in infection
in the majority of individuals. Furthermore, levels of ADCD, ADCT, ADCC increased over time
while ADCP remained high throughout 3 years of infection. Other studies that have examined
the kinetics of ADCC [36, 67–69] and ADCP [70–72] from acute to chronic HIV infection have
shown inconsistent results with some showing higher activity early in infection while others sug-
gest, similar to our study, that these activities increase over time. These differences are likely due
to the use of a variety of assays and antigens and supports the efforts being made to standardise
Fc effector assays [43]. Interestingly, we found differences in Fc effector functions between
bNAb and no-bNAb individuals at 6 months post-infection prior to the development of neutral-
ization breadth. Other factors previously shown to be associated with neutralization breadth,
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such as high viral load and low CD4 count, in this and other cohorts, were also seen early in
infection [12, 14, 18, 20]. However, at 3 years post-infection we found no differences in Fc effec-
tor function between the two groups further highlighting that events early in HIV infection are
signatures, but not necessarily drivers, for the later development of neutralization breadth.
Fig 5. Multivariate classifications reveal that individuals who develop bNAbs can be reliably identified by their Fc features at 6 months of infection. (A)
Principal components analysis of 13 bNAb (red) and 10 no-bNAb (blue) using 17 variables. Individual CAPRISA identifiers are shown, with component 1 and 2
explaining 52.3% of the variance in the data set. (B) Confusion matrix showing the classification of bNAb and no-bNAb individuals achieved by random forest
classification. Shown are the numbers of individuals for each predicted or observed group with correct classifications indicated in color and misclassifications
indicated in white. The 2 bNAb (CAP257 and CAP292) and 2 no-bNAb (CAP88 and CAP228) individuals that were incorrectly classified can be seen in 5A. (C)
Importance of the features employed in the random forest classification is indicated by the mean decrease in Gini importance weighting. (D) The model was
verified by permutation testing following random shuffling of the classification data 100,000 times. The dashed line indicates the accuracy of the proposed model
(82.6%), with shuffles resulting in accuracy greater than this shown as a proportion of the total shuffles (0.38%).
https://doi.org/10.1371/journal.ppat.1006987.g005
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Positive correlations between different Fc effector functions have previously been reported
among elite controllers and vaccinees in the RV144 trial suggesting a co-ordinated immune
response in these groups [5, 44]. Our study showed that while bNAb individuals did not show
significant concordance between Fc functions there was also no significant discordance between
the various functions. This differentiated them from no-bNAb individuals who showed signifi-
cant discordance, which has also been seen in chronic HIV infection [43]. Only one other study
has examined Fc effector function in the context of neutralization breadth and found that
ADCC did not differ between the groups, similar to our findings [69]. Here we extend this to
examine additional Fc effector functions and find that bNAb individuals could be distinguished
from no-bNAb individuals by having higher levels of ADCD and ADCT at 6 months of infec-
tion. Recent data suggested that ADCD may have been a correlate of reduced risk in RV144 as a
result of V2-specific antibodies efficiently activating complement [73]. In our study, ADCD was
strongly correlated with total HIV-specific IgG levels which may have facilitated increased IgG
complex formation in individuals that develop bNAbs [74]. Furthermore, binding of C3 com-
ponents to CR2 (complement receptor 2) on the surface of follicular dendritic cells (FDC) in
the germinal center facilitates the presentation of antigen to B cells during the processes of affin-
ity maturation and isotype switching [75, 76]. Thus our finding of higher levels of C3b deposi-
tion by IgG present in bNAb individuals could contribute to increased antigen presentation
through binding to CR2 on FDCs. In contrast, increased ADCT was not due to higher IgG lev-
els although it was the only Fc effector function that showed a correlation with a single IgG sub-
class, namely IgG3. Since IgG3 preferentially binds to higher affinity polymorphic variants
FcγRIIa-H131 and FcγRIIIa-V158 this may explain the associations we observed between bind-
ing to these receptors and ADCT. While the role of Fc-mediated trogocytosis in HIV infection
has not yet been explored, one potential mechanism that has been reported in studies of cancer
is that repeated “nibbling” of membrane proteins on tumorigenic cells by effector cells can
result in cell killing [27]. Others have shown ADCT facilitates the deposition of “snatched” anti-
gen-specific IgG on the surface of effector cells, potentially increasing antigen presentation for
T cell help [77–79]. Whether either of these mechanisms contributed to the development of
neutralization breadth will require an analysis of the antigens captured by ADCT and if these
are able to enhance HIV-specific immune responses when deposited on antigen-naïve cells.
The relative abundance of IgG2 and IgG4 was higher in bNAb individuals across multiple
HIV antigens and this correlated with neutralization breadth. In support of this, we found that
antibodies from bNAb individuals had higher binding to FcγRIIa-H131 and FcγRIIIa-V158 as
compared to the respective lower affinity polymorphic variants R131 and F158. H131 and
V158 are known to bind more efficiently to IgG2 and IgG4 respectively although these levels
are still significantly lower than IgG1 and IgG3 [63, 80]. This may reflect increased relative
abundance of these subclasses in bNAb individuals which may also explain why we saw no dif-
ferences in ADCC. Both IgG2 and IgG4, located downstream of IgG3 and IgG1 on chromo-
some 14 [81, 82], have been shown to dampen down the inflammatory response by competing
with IgG1 [83, 84]. Furthermore, IgG4 binds FcγRIIb, the only inhibitory Fc receptor, with a
higher affinity than all other subclasses [80]. Thus the use of multiple IgG subclasses in bNAb
individuals may help to balance the highly pro-inflammatory activities of IgG1 and IgG3 early
in infection, increasing the diversity of the antibody response [85] and potentially promoting
events that are required for later development of neutralization breadth. Although HIV-spe-
cific IgG2 and IgG4 showed greater relative abundance, it should be noted that both were still
present at very low levels compared to IgG1 and IgG3. Despite this and the fact that IgG2 and
IgG4 have reduced Fc effector functionality, subclass diversity in this study still correlated with
overall Fc polyfunction. An excess of IgG2 and IgG4 is thought to have compromised the effec-
tiveness of gp120 vaccines possibly due to competition with IgG1 and IgG3 [5, 86, 87]. Thus,
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in current vaccination strategies we may lack the balance of subclass diversity required to sup-
port bNAb development. Indeed, others have found higher isotype diversity, specifically IgG2
levels, among viremic controllers suggesting that a balance of IgG subclasses is a key factor in
immune function [82, 85, 88]. Alternatively, subclass diversity may be a secondary conse-
quence of elevated AID activity in individuals with bNAbs. If so, then somatic hypermutation
required for bNAb development may come at the expense of IgG1/3 dominance because of
increased downstream class switching. Irrespective of the cause, subclass diversity is an impor-
tant consideration for pathogenic outcomes and may have implications in vaccination strate-
gies [82].
Similar to others, we found that levels of CXCL13 were higher in bNAb individuals early in
infection suggesting that this cytokine provides important signals for bNAb development [20,
21, 56, 66]. However, we are the first to examine the relationship between CXCL13 and Fc
effector function and find that it correlated more strongly with Fc effector function than with
neutralization breadth. Since CXCL13 is necessary for migration of B cells to germinal centers
where clonal selection, somatic hypermutation and class-switching occurs, these data suggest
that the Fc region of bNAbs are subjected to similar processes. AID plays a more direct role in
facilitating somatic hypermutation and class switching explaining the correlation we observed
with neutralization breadth as well as subclass diversity of the Fc. Cohen and colleagues have
previously shown that AID transcripts were higher in bNAb individuals by ex vivo transcrip-
tional profiling [20]. Here we show using the different approach of flow cytometry, that
expression of the AID enzyme in activated B cells from bNAb individuals is higher than no-
bNAb individuals. Collectively, these data indicate that immune factors associated with germi-
nal centers drive diversification of both Fab and Fc functions.
The Fab and Fc regions are encoded by different genes and class switch recombination pro-
duces new effector function in the context of an existing antibody specificity suggesting inde-
pendent evolution of these two portions. However, several groups have shown that the isotype
or subclass of the constant region can subtly affect Fab function such as neutralization and
avidity across various diseases [89–92]. In addition, class-switch recombination and somatic
hypermutation both require AID to target transcription and DNA cleavage respectively [10].
Our study provides evidence for similar modulation of the Fc and the Fab driven by AID in
the context of an HIV-specific polyclonal response. In our model, we show that HIV-specific
binding to Fc receptors, Fc polyfunctionality and total HIV-specific IgG levels were among the
top five features that classify bNAb individuals. Among these, low CD4 count and high HIV-
specific IgG levels have been previously associated with the development of neutralization
breadth [12, 13]. Our data support findings from other cohorts showing correlations between
neutralization breadth with immunologic analytes, such as CXCL13 [21, 66]. However, we are
the first to describe that enhanced complement deposition and trogocytic activity are associ-
ated with the development of neutralizing antibodies, which will need to be confirmed in
other cohorts. Furthermore, we showed, through adsorption experiments, that bNAbs in one
individual were also responsible for Fc effector functions. Whether these functions are medi-
ated by the same or separate antibody molecules will require further study, preferably via the
isolation of HIV-specific monoclonal antibodies with their native Fc regions. Nevertheless,
our finding that the Fab and Fc functions may be jointly regulated in individuals with bNAbs
could be important in the context of vaccination where the aim is to induce a polyclonal
response with both neutralizing and Fc effector functionality.
Overall, this study illustrates that the functions and characteristics of the antibody Fc were
able to reliably classify bNAb individuals. Furthermore, early Fc function and subclass diver-
sity predicted which HIV-infected individuals went on to develop bNAbs. Unlike broad neu-
tralization, Fc-mediated activities were present in all individuals and suggests that favourable
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Fc effector function could be elicited as a prelude to a bNAb response which is encouraging
for vaccination strategies. Additional studies are required to understand how neutralization
and Fc effector functions can be favourably tuned to produce a protective polyclonal response.
Our data suggests that common immune factors underlie the development of both neutraliza-
tion breadth and Fc effector function. Moreover, as Fc effector function differences occur well
before the development of neutralization breadth, these properties could be used to identify
individuals with the necessary germinal center activity to respond to a vaccine aimed at the
generation of bNAbs.
Materials and methods
Ethics statement
CAPRISA 002 and 004 acute HIV infection cohorts were approved by the Biomedical Research
Ethics Committee of the University of KwaZulu-Natal (M160791) and this specific study was
approved by the Human Research Ethics Committee of the University of the Witwatersrand
(M150313). All participants were adults and provided written informed consent to have their
stored samples used for future studies. All healthy subjects in this study were adults and pro-
vided written informed consent to obtain both PBMCs (peripheral blood mononuclear cells)
and plasma and have their samples stored for future use.
Sample preparation and definition of neutralizing breadth
Serum from participants in the CAPRISA 002 and 004 acute HIV infection cohorts [93, 94]
were previously screened for neutralization breadth using a 44 virus multi-clade panel [12].
Samples from individuals able to neutralize at least 40% of a 44 virus panel at 3 years post-
infection were defined as having developed bNAbs. Individuals with no-bNAbs were also
matched based on viral load at 6 months and were not significantly different at all time points
tested (S1A Fig). By these criteria, we included plasma samples from 13 bNAb and 10 no-
bNAb individuals at 6 months, 1 year and 3 years post-infection (S1 Table). IgG was isolated
from plasma using Protein G according to the manufacturer’s instructions in order to elimi-
nate the cofounding impact of cytokines or plasma proteins on cell-based assays, quantified by
a nanodrop spectrophotometer (Pierce Biotechnology, Rockford, IL) and confirmed by IgG
ELISA. Pooled IgG from HIV-positive samples from the NIH AIDS Reagent programme
(HIVIG) was used in all assays to normalise for plate to plate variation while samples from 5
HIV-negative individuals from the same cohort were used as negative controls.
Proteins and peptides
Plasmids encoding histidine-tagged recombinant gp120 from ConC and gp120 from CAP45.
G3 envelope sequences were transfected using polyethylenimine 25 kDa (Polysciences Inc,
Warrington, PA) into HEK293T cells obtained from Dr George Shaw (University of Alabama,
Birmingham, AL). Cells were cultured at 37˚C, 5% CO2 in DMEM containing 10% heat-inac-
tivated fetal bovine serum (Gibco, Gaithersburg, MD) with 50 μg/ml gentamicin (Sigma-
Aldrich, St Louis, MO) and disrupted at confluency by treatment with 0.25% trypsin in 1 mM
EDTA (Sigma-Aldrich, St Louis, MO). Recombinant proteins were expressed and purified as
previously described [95]. BG505 SOSIP.664 gp140 trimer was produced in HEK293F suspen-
sion cells (Invitrogen) and purified by size exclusion chromatography (SEC) [96]. Prior to use
trimer was subject to quality control by ELISA binding of CAP256-VRC26.25 and PGT151
and the lack of binding to F105. The C.ZA.1197MB strains of gp41, p24 and gp140 was pur-
chased from Immune Tech (Lexington, New York), CAP88. B5 V3 peptide, CAP248 MPER
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peptide and MPR.03 were purchased from Peptide 2.0 (Chantilly, Virginia). V1V2 scaffolded
proteins were expressed in HEK293S cells (ATCC CRL-3022 N-acetylglucosaminyltransferase
I deleted), grown in a shaking incubator at 37˚C, 5% CO2, 70% humidity at 125rpm. Cultures
were harvested after seven days and purified by sequential Ni-NTA and SEC.
Viral divergence and diversity analysis
Measurement of divergence of autologous viral sequences from antigens was done using avail-
able transmitted/founder or acute gp120 viral sequences from 10/13 bNAb and 7/10 no-bNAb
individuals which were aligned using MUSCLE (MUltiple Sequence Comparison by Log-
Expectation https://www.ebi.ac.uk/Tools/msa/muscle/). A script adapted from SONAR (Soft-
ware for the Ontogenic aNalysis of Antibody Repertoires) [97] was adapted to calculate the
percentage nucleotide differences of autologous viruses compared to the antigen sequences
(ConC gp120, C.ZA.1197MB gp140 and CAP45.G3 gp120).
Diversity in gp160 was estimated using longitudinal sequences from 8 bNAb and 5 no-
bNAb individuals. This included sequences from 6 (between 5 and 28 per individual), 12
(between 8 and 30 per individual) and 36 months (between 5 and 19 per individual) post-
infection. CAP256 was superinfected and sequences from both the primary and superinfecting
viruses were included. Mean pairwise genetic distances between sequences were calculated
using MEGA v7 [98].
Antibody dependent cellular phagocytosis assay (ADCP)
The THP-1 phagocytosis assay was performed as previously described [99] using 1μM neutravi-
din beads (Molecular Probes Inc, Eugene, OR) coated with gp120 ConC, gp120 CAP45.G3 or
gp140 C.ZA.1197MB. Polyclonal IgG samples were titrated and tested at a final concentration of
100μg/ml. Phagocytic scores were calculated as the geometric mean fluorescent intensity (MFI)
of the beads multiplied by the percentage bead uptake. This, including all other flow cytometry
work was completed on a FACSAria II (BD biosciences, Franklin Lakes, New Jersey). THP-1
cells were obtained from the NIH AIDS Reagent Program and cultured at 37˚C, 5% CO2 in
RPMI containing 10% heat-inactivated fetal bovine serum (Gibco, Gaithersburg, MD) with 1%
Penicillin Streptomycin (Gibco, Gaithersburg, MD) and not allowed to exceed 4 x 105 cells/ml.
Antibody dependent cellular cytotoxicity (ADCC)
ADCC activity was detected by the previously described ADCC-GranToxiLux (GTL) assay
using antigen-coated cells [100]. This assay was chosen as it is high-throughput and has been
previously validated. Whole PBMCs from a healthy donor were used as effector cells. The
FcγRIIIa receptor was genotyped as being homozygous for valine at position 158 by the TaqMan
SNP genotyping assay (rs396991) (Applied Biosystems, Foster City, CA) to ensure high levels of
lysis. Target CEM-NKR.CCR5 (CEM-natural killer resistant T lymphoblast cell line transduced
with CCR5) cells were coated with gp120 ConC and gp140 C.ZA.1197MB at 2.5μg/ml and
10μg/ml respectively. Optimal coating concentration was determined by titration of the antigen
and measuring residual levels of unbound CD4 with anti-CD4 FITC (SK3 clone, BD Biosci-
ences). MAb A32 was used as a positive control with Palivizumab (MedImmune, LLC; Gaithers-
burg, MD) used as negative control. The results, analysed in FlowJo (FlowJo LLC, Ashland,
Oregon) are expressed as % Granzyme B (GzB) activity, defined as the percentage of cells posi-
tive for proteolytically active GzB out of the total viable target cell population. The final results
are expressed after subtracting the background represented by the % GzB activity observed in
wells containing effector and target cell populations in the absence of IgG. CEM-NKR.CCR5
cells were obtained for the NIH AIDS Reagent programme and were cultured at 37˚C, 5% CO2
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in RPMI containing 10% heat-inactivated fetal bovine serum (Gibco, Gaithersburg, MD) with
1% Penicillin Streptomycin (Gibco, Gaithersburg, MD).
Antibody dependent complement deposition (ADCD)
ADCD was determined by the deposition of the complement component C3b on the surface of
CEM-NKR.CCR5 cells [3]. Target cells were pulsed with 6μg gp120 ConC, 14μg gp120 CAP45.
G3 or 6μg gp140 C.ZA.1197MB in 100μl of R10 media (10% FBS 1% Pen/Strep RPMI, Gibco,
Gaithersburg, MD) determined by titration as described above for 1 hour at room temperature
and incubated with 100μg/ml of IgG preparation. HIV-negative plasma was used as a source of
complement and diluted 1 in 10 in 0.1% gelatin/ veronal buffer (Sigma-Aldrich, St Louis, MO)
and 150μl added and incubated for 20 minutes at 37˚C. The cells were then washed in 15mM
EDTA in PBS and C3b was detected by flow cytometry using an anti-human/mouse comple-
ment component C3/C3b/iC3b mAb (Cedarlane, Burlington, Canada). Unpulsed cells were
used as background controls and HIV-negative plasma was heat-inactivated at 56˚C to remove
complement as a negative control. The ADCD score was defined as geometric MFI multiplied
by % cells positive for C3b deposition.
Antibody dependent cellular trogocytosis (ADCT)
CEM-NKR.CCR5 cells were pulsed with gp120 ConC (2.5μg/ml), gp120 CAP45.G3 (25μg/ml) or
gp140 C.ZA.1197MB (10μg/ml) for 75 minutes at room temperature. Optimal coating concen-
trations were determined as described above. Cells were stained with PKH26 dye (Paul Karl
Horan 26 dye) as per instructions from the manufacturer (Sigma-Aldrich, St Louis, MO) and
resuspended at 2 million cells/ml. IgG at a final concentration of 100μg/ml were added to the
cells and incubated for 30 minutes at 37˚C. THP-1 cells were stained with intracellular CFSE
(carboxyfluorescein succinimidyl ester) and 150μl at 6.7 x 105 cells/ml was added to the plate and
incubated for a further hour at 37˚C. Cells were then washed with 15mM EDTA in PBS. Flow
cytometry was used to distinguish PKH26+ CFSE+ THP-1 cells (i.e. the uninfected monocytes
that have received membrane fragments from the coated cells) and are represented as a propor-
tion of total THP-1 cells. Doublets were excluded from the analysis by singlet gating (Richardson,
et al., submitted). The assay was gated on stained CEM and THP-1 cells incubated in the absence
of IgG to ensure that we did not measure antibody-independent trogocytosis. Uncoated PKH26
stained CEM cells were also incubated with THP-1 cells in the presence of HIV-specific IgG in
order to ensure that the responses seen were HIV-specific. HIV-negative IgG as well as Palivizu-
mab were used as negative controls while HIVIG was used to standardise between runs.
Adsorption of neutralizing activity
Adsorption of broadly neutralizing antibodies that target the N332 glycan from isolated
plasma IgG was performed as previously described [101]. For this we used ST09 (1gut-mV3
scaffold), a V3 scaffold that specifically binds N332-directed bNAbs [102] (a gift from Dr Peter
Kwong, Vaccine Research Center, NIH, USA) covalently coupled to tosyl-activated magnetic
beads. Following adsorption, the depletion of anti-ST09 (1gut-mV3 scaffold) activity was mea-
sured by ELISA and reduction of neutralization was confirmed by neutralization assay as
described elsewhere [103].
Customised multiplex IgG subclass assay and Fc binding array
A customised multiplex assay was used as previously described [104]. Briefly, Multiplex micro-
plex carboxylated beads (Luminex, Madison, WI) were coupled to 12 HIV specific antigens.
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Fifty μl of a 100 microspheres/μl bead preparation was incubated with purified IgG overnight
(100μg/μl) at 4˚C. Levels of bulk IgG and IgG1-IgG4 were detected by PE-conjugated detection
agents (Southern Biotech, Birmingham, AL) by a Bio-Plex200. The mean of PBS only samples
added to 3 times the standard deviation was subtracted from all samples.
Similarly, for the Fc binding array, HIV-specific antigen coated microspheres (10 beads/μl)
were added to 5μg/ml of purified IgG in black clear bottom 384-well black plates in replicate
and incubated for 2 hours. Antigen binding to FcγRIIa (H131/R131), FcγRIIb, FcγRIIIa
(F158/V158), FcγRIIIb (NA2) and C1q was detected by incubating the tetrameric PE-conju-
gated reagents (as described elsewhere [57]) for an hour. HIVIG was used as a positive control
and to track plate-to-plate variation.
CXCL13 ELISA
CXCL13 was detected in plasma using the Human CXCL13 Quantikine ELISA Kit (R&D Sys-
tems) as described by the manufacturer.
Activation-induced cytidine deaminase (AID) detection
PBMCs from selected individuals were thawed in the presence of Benzonase Nuclease (Novagen,
Madison, WI) and rested overnight at 37˚C. Half a million cells in 200μl of RPMI-10 media was
stimulated with 0.5uM TLR9 agonist ODN-2006 (Invivogen, San Diego, CA) for 3 days at 37˚C.
A total of 1–3 million cells for both the stimulated and unstimulated controls were pooled after
3 days for flow cytometric staining. Surface staining was performed in PBS/0.1% BSA including
CD16, CD14, CD3 (APC-CY7), CD19 (PE-CY7), IgD (FITC), CD38 (PE-CY5) (BD Pharmin-
gen, Franklin Lakes, NJ) and was followed by intracellular staining using the BD Cytofix/Cyto-
perm kit as per the instructions from the manufacturer for AID (AF647, BD) and Ki67 (PerCP.
Cy5, eBiosciences, San Diego, CA). B cells were defined as lymphocytes, single cells, live cells
(LIVE/DEAD Fixable Dead Cell Stain), CD3-/CD16-/CD14- (APC-CY7), CD19+ (PE-Cy7). A
HIV-negative control donor PBMC sample was run in each set of experiments to ensure consis-
tency between runs.
Statistical analysis
Fc polyfunctionality Z-scores were calculated by standardising each Fc effector function
(where the mean of the function is subtracted from the individual value and divided by the
standard deviation of the mean) and then adding all the Z-scores for each function per individ-
ual. All comparisons between groups were done with non-parametric tests including Mann-
Whitney U tests (for two groups) and Kruskal-Wallis tests with Tukey’s correction for multiple
comparison and all confidence intervals were at 95%. All correlations reported are non-
parametric Spearman’s correlations and all statistical analysis was done with two-sided testing
with an alpha level of 0.05. Univariate analysis was performed using GraphPad 6 (GraphPad
Software, Inc, La Jolla, CA). For the multivariate analysis, the mean added to 3 standard devia-
tions of the mean of HIV-negative samples for HIV-specific experiments was subtracted from
HIV-positive data at 6 months post-infection and was then standardised by Z-score prior to
analysis. In addition, P-values of Spearman’s correlations with bNAb and no-bNAb groups
was corrected for multiple comparisons by adjusting alpha levels using the false discovery rate
(where the FDR was 5%) and Benjamini–Hochberg procedure [105]. Significant features were
used in a principal components analysis (PCA) using JMP13 from SAS (Cary, NC). No missing
data was imputed. Significant features only were again used to classify individuals into groups
in order to decrease overfitting and was done by random forest classification using the R pack-
age ‘randomForest’ with the number of trees set at 500 and cross-validation indicated by out-
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of-bag estimate. Feature weighting or importance in the classification was represented by the
mean decrease of Gini importance which measures the average gain of purity by splits of a
given variable. If the variable is useful it tends to give a relatively large decrease in mean Gini-
gain [106]. The resulting confusion matrix was constructed by using the ‘ggplot2’ package. The
model was validated by permutation testing performed in R with 100000 data shuffles.
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S1 Fig. Viral load, divergence and diversity analysis in bNAb and no-bNAb individuals.
(A) Matched viral loads of bNAb (red) and no-bNAb groups (blue) at 6 months post-infection.
(B) Percentage divergence of autologous viral gp120 sequences from the antigen sequences of
ConC, C.ZA.1197MB and CAP45.G3 among 10 bNAb and 7 no-bNAb individuals. (C) Diver-
sity analysis of gp160 sequences among 8 bNAb and 5 no-bNAb individuals at 6, 12 and 36
months post-infection were calculated using mean pairwise genetic distances. Significant dif-
ferences were calculated by Kruskal-Wallis test (n.s. = non-significant).
(PDF)
S2 Fig. Fc effector function over time in bNAb and no-bNAb individuals. ADCP (% bead
uptake x MFI), ADCD (% C3b deposition x MFI), ADCT (% PKH-26+CFSE+ cells) and ADCC
(% Granzyme B) levels were measured against 3 HIV-specific antigens for 13 bNAb individuals
(shown in red) and 10 no-bNAb individuals (shown in blue) at 6, 12 and 36 months post-infec-
tion. Grey horizontal bars indicate significant comparisons between the groups at single time
points (Mann-Whitney U test) and black bars indicate comparisons within each group over
time (Kruskal-Wallis test with Tukey´s multiple comparison correction). <0.05, <0.001,
<0.0001. Data are representative of 3 independent experiments. Dotted horizontal lines indi-
cate 3 standard deviations of the mean of the HIV-negative samples.
(PDF)
S3 Fig. Broadly neutralizing plasma antibodies mediate Fc effector functions. (A) Antibod-
ies that mediate broad neutralization in CAP255 at 3 years post-infection were adsorbed out
by ST09 (1gut-mV3 scaffold) as shown by the loss of neutralization against viral isolate Q23.17
(dotted line) compared to unadsorbed IgG (blank solid line). (B) Unabsorbed IgG (solid) and
absorbed IgG (dashed) were measured for Fc effector functions and significant depletion of
these functions is shown as p<0.001; p<0.05; p<0.001 respectively (one-way ANOVA
with Tukey correction).
(PDF)
S4 Fig. Concordance of Fc functions among bNAb and no-bNAb individuals. (A) Spear-
man´s correlation between the Fc polyfunctionality Z-scores using gp120 ConC and gp140 C.
ZA.1197MB where red indicates bNAb and blue no-bNAb individuals. (B) Spearman´s corre-
lation between the Fc polyfunctionality Z-score using gp140 C.ZA.1197MB and neutralization
breadth where dotted trend lines are indicated. (C) Spearman correlation coefficients between
Fc effector functions against gp120 ConC in bNAb individuals (n = 13) and no-bNAb individ-
uals (n = 10) at 6 months post-infection with positive R values shown in purple and negative in
green. Color intensity indicates strength of the correlation and significant associations are
shown as p<0.05 and p<0.001.
(PDF)
S5 Fig. Correlations between HIV-specific IgG levels and Fc effector functions. (A) Anti-
gen-specific total IgG levels were measured by Luminex with significant differences between
groups indicated as <0.05, <0.01, <0.0001 by Kruskal-Wallis test and Tukey multiple
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correction. Medians and interquartile ranges are indicated. (B) Correlations between gp120
ConC-specific Fc effector functions and gp120 ConC-specific IgG levels (MFI) are shown at 6
months post-infection. Significant Spearman’s correlations are shown in red and p<0.001;
p = 0.01. Dotted trend lines are indicated and results are representative of 2 independent
experiments.
(PDF)
S6 Fig. HIV-specific antigen binding of IgG subclasses in bNAb and no-bNAb individuals.
Abundance of IgG1-4 subclasses relative to total antigen specific IgG of bNAb (red) and no-
bNAb (blue) individuals shown in columns against 12 HIV antigen shown in rows. Signifi-
cance between groups was determined by Mann-Whitney U test where p<0.05.
(PDF)
S7 Fig. Gating strategy to define AID-expressing B cells by flow cytometry. (A) Representa-
tive flow cytometry plots showing PBMCs gated on lymphocytes and single B cells on CD19
+ CD3/CD16/CD14. Live B cells were then gated on AID and Ki67. FMO controls for AID and
Ki67 as well as an unstimulated and TLR9 stimulated data set are shown. (B) Percentage of AID
expressing B cells in 6 bNAb, 6 no-bNAb and 4 HIV-negative individuals that were unstimu-
lated (UN) or stimulated with TLR9 for 3 days. (n.s. = non-significant, Kruskal-Wallis test).
(PDF)
S1 Table. Participants with and without bNAbs included in this study.
(PDF)
S2 Table. List of variables significantly associated with bNAb individuals adjusted for mul-
tiple comparisons. Significant variables after adjustment by the Benjamini–Hochberg (BH)
procedure are shown in bold with their corresponding adjusted p-value shown in italics.
(PDF)
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